Cargando…
Trans-arterial hepatic radioembolisation of yttrium-90 microspheres
The liver represents a frequent site for metastatic disease, in addition to being a site for primary cancer. Hepatic metastases from certain neoplasms, such as colon, neuroendocrine, melanoma and gastrointestinal stromal tumour have a distinct predilection to metastasize the liver, which in many cas...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Department of Biomedical Imaging, Faculty of Medicine, University of Malaya, Malaysia
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3097629/ https://www.ncbi.nlm.nih.gov/pubmed/21614250 http://dx.doi.org/10.2349/biij.2.3.e43 |
_version_ | 1782203854464483328 |
---|---|
author | Murthy, R Habbu, A Salem, R |
author_facet | Murthy, R Habbu, A Salem, R |
author_sort | Murthy, R |
collection | PubMed |
description | The liver represents a frequent site for metastatic disease, in addition to being a site for primary cancer. Hepatic metastases from certain neoplasms, such as colon, neuroendocrine, melanoma and gastrointestinal stromal tumour have a distinct predilection to metastasize the liver, which in many cases may represent the only or the dominant site of disease. In these circumstances, cytoreduction via surgery or in situ ablative techniques aims to influence the natural history of the disease progression and improve clinical outcomes. Liver directed therapy utilising yttrium-90 microspheres represents a recently introduced in situ multidisciplinary cancer therapy that has caught the attention of many physicians faced with the challenges of treating these complex patients. Although similar to other forms of trans-arterial liver directed therapy, there are discrete differences and potentially fatal treatment consequences unique to this therapy. This objective of this review article is to provide the reader a basis for understanding the therapeutic principles, patient exclusion criteria, pre and post therapy investigations and salient clinical results in the two most commonly treated disease types; metastatic colorectal cancer and hepatocellular cancer. |
format | Text |
id | pubmed-3097629 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Department of Biomedical Imaging, Faculty of Medicine, University of Malaya, Malaysia |
record_format | MEDLINE/PubMed |
spelling | pubmed-30976292011-05-24 Trans-arterial hepatic radioembolisation of yttrium-90 microspheres Murthy, R Habbu, A Salem, R Biomed Imaging Interv J Review Article The liver represents a frequent site for metastatic disease, in addition to being a site for primary cancer. Hepatic metastases from certain neoplasms, such as colon, neuroendocrine, melanoma and gastrointestinal stromal tumour have a distinct predilection to metastasize the liver, which in many cases may represent the only or the dominant site of disease. In these circumstances, cytoreduction via surgery or in situ ablative techniques aims to influence the natural history of the disease progression and improve clinical outcomes. Liver directed therapy utilising yttrium-90 microspheres represents a recently introduced in situ multidisciplinary cancer therapy that has caught the attention of many physicians faced with the challenges of treating these complex patients. Although similar to other forms of trans-arterial liver directed therapy, there are discrete differences and potentially fatal treatment consequences unique to this therapy. This objective of this review article is to provide the reader a basis for understanding the therapeutic principles, patient exclusion criteria, pre and post therapy investigations and salient clinical results in the two most commonly treated disease types; metastatic colorectal cancer and hepatocellular cancer. Department of Biomedical Imaging, Faculty of Medicine, University of Malaya, Malaysia 2006-07-01 /pmc/articles/PMC3097629/ /pubmed/21614250 http://dx.doi.org/10.2349/biij.2.3.e43 Text en © 2006 Biomedical Imaging and Intervention Journal http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Murthy, R Habbu, A Salem, R Trans-arterial hepatic radioembolisation of yttrium-90 microspheres |
title | Trans-arterial hepatic radioembolisation of yttrium-90 microspheres |
title_full | Trans-arterial hepatic radioembolisation of yttrium-90 microspheres |
title_fullStr | Trans-arterial hepatic radioembolisation of yttrium-90 microspheres |
title_full_unstemmed | Trans-arterial hepatic radioembolisation of yttrium-90 microspheres |
title_short | Trans-arterial hepatic radioembolisation of yttrium-90 microspheres |
title_sort | trans-arterial hepatic radioembolisation of yttrium-90 microspheres |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3097629/ https://www.ncbi.nlm.nih.gov/pubmed/21614250 http://dx.doi.org/10.2349/biij.2.3.e43 |
work_keys_str_mv | AT murthyr transarterialhepaticradioembolisationofyttrium90microspheres AT habbua transarterialhepaticradioembolisationofyttrium90microspheres AT salemr transarterialhepaticradioembolisationofyttrium90microspheres |